SynthesisRadiation oncology (London, England)2026
Advances in predictive factors for pathological complete response after neoadjuvant therapy in locally advanced rectal cancer.
Synthesis in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial fitness in circulating T cells predicts neoadjuvant therapy response in locally advanced colorectal cancer.Gastroenterology report · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For locally advanced rectal cancer (LARC), neoadjuvant chemoradiotherapy (nCRT) combined with total mesorectal excision has emerged as the standard therapeutic approach, as delineated in contemporary clinical guidelines. Pathological complete response (pCR) serves as a pivotal metric for assessing nCRT efficacy, with strong correlations to long-term survival outcomes and organ preservation strategies such as the "watch-and-wait" approach. However, inter-individual variability in treatment responses results in only approximately 20% of patients attaining pCR following nCRT. Accurate identification of these patients is imperative not only for optimizing therapeutic efficacy but also for substantially augmenting patient survival benefits. This article conducts a systematic review of domestic and international literature to synthesize the current research landscape regarding pCR predictive factors in LARC patients post-nCRT across five dimensions: patient-specific characteristics, tumor clinicopathological features, hematological markers, imaging modalities, molecular biomarkers, and multidimensional integrated predictive models. The review emphasizes the synergistic potential of integrating traditional clinical parameters with emerging radiomics, multi-omics biomarkers, and artificial intelligence algorithms. It seeks to furnish a theoretical foundation and reference framework for the development of personalized precision treatment strategies, optimization of therapeutic pathways, and maximization of organ preservation opportunities in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.